Core Insights - Halberd Corporation, in collaboration with Athena Telemedicine Partners, is conducting a 100-patient study to evaluate the efficacy of its patent-pending LDX compound for treating dialysis-borne neuropathy and pruritis [1][5] - The global kidney disease market is substantial, with approximately 850 million people affected worldwide, highlighting a significant opportunity for LDX's applications [3][4] - The global dialysis treatment market was valued at approximately $116.1 billion in 2024 and is projected to reach $198.2 billion by 2033, growing at a CAGR of 5.4% [4] Company Developments - The LDX compound has shown promising results in managing various conditions, including addiction and chronic inflammatory disorders, indicating a multibillion-dollar market potential [2] - A case report demonstrated that a 63-year-old female patient with Stage 4 chronic renal failure experienced immediate symptom relief after being treated with LDX [5][6] - The company plans to offer a 90-day trial for clinicians to assess the safety and efficacy of LDX in dialysis patients [7] Industry Context - As of 2023, approximately 4.2 million people worldwide are undergoing dialysis treatments for end-stage kidney failure, with a notable increase in home dialysis services since the COVID-19 pandemic [4] - The International Society of Nephrology estimates that 13.3 million people experience acute kidney injury annually, which can lead to chronic kidney disease or kidney failure if not managed properly [4] - The partnership with Athena GTX includes the use of wearable monitoring technologies to collect objective data on symptom relief for patients [8]